Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage III NSCLC
Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recom…
Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recom…
Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CSton…
Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and…
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to ann…
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CS…
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to ann…
Ewopharma, a pharmaceutical marketing company and Eisai Europe Ltd., a leading global research and development-based pha…
Tuberculoza (TBC) este principala cauză de deces provocat de o boală infecțioasă, la nivel global.[1] Otsuka Pharmaceuti…
Ewopharma and Vianex S.A. are pleased to announce their new partnership for distribution of Amikacin in Switzerland. Ewo…
Ewopharma and Vianex S.A. are pleased to announce their new partnership for distribution of Amikacin in Switzerland. Ewo…